Dose proportionality and bioavailability of quinoxaline-based JNK inhibitor after single oral and intravenous administration in rats; Xenobiotica; Vol. 54, iss. 1
| Parent link: | Xenobiotica.— .— London: Taylor & Francis Group Vol. 54, iss. 1.— 2024.— P. 18-25 |
|---|---|
| Müşterek Yazar: | |
| Diğer Yazarlar: | , , , , , |
| Özet: | Title screen The dose proportionality and bioavailability of the potential anti-inflammatory and neuroprotective JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) were evaluated by comparing pharmacokinetic parameters after single oral (25, 50 and 100 mg/kg) and intravenous (1 mg/kg) IQ-1 administration in rats. IQ-1 and its major metabolite ketone 11H-indeno[1,2-b]quinoxalin-11-one (IQ-18) were isolated from plasma samples by liquid–liquid extraction. IQ-1 (E-isomer) and IQ-18 were simultaneously quantified in plasma by the validated method of liquid chromatography with triple quadrupole mass spectrometry (HPLC–MS/MS). The absolute bioavailability of IQ-1 was < 1.5%. Cmax values were 24.72 ± 4.30, 25.66 ± 7.11 and 37.61 ± 3.53 ng/mL after single oral administration of IQ-1 at doses of 25, 50 and 100 mg/kg, respectively. IQ-1 exhibited dose proportionality at 50–100 mg/kg dose levels, whereas its pharmacokinetics was not dose proportional over the range of 25–50 mg/kg. IQ-18 demonstrated the invariance of the dose-normalized Cmax. In this study we systematically elucidated the absorption characteristics of IQ-1 in rat gastrointestinal tract and provided better understanding of IQ-1 pharmacology for the future development of a new formulations and therapeutic optimisation. Текстовый файл AM_Agreement |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
2024
|
| Konular: | |
| Online Erişim: | https://doi.org/10.1080/00498254.2023.2299686 |
| Materyal Türü: | Elektronik Kitap Bölümü |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=672937 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 672937 | ||
| 005 | 20240605145203.0 | ||
| 090 | |a 672937 | ||
| 100 | |a 20240605d2024 k||y0engy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a GB | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Dose proportionality and bioavailability of quinoxaline-based JNK inhibitor after single oral and intravenous administration in rats |f G. A. Frelikh, E. A. Yanovskaya, A. P. Lakeev [et al.] | |
| 203 | |a Текст |c электронный |b визуальный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 30 tit. | ||
| 330 | |a The dose proportionality and bioavailability of the potential anti-inflammatory and neuroprotective JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) were evaluated by comparing pharmacokinetic parameters after single oral (25, 50 and 100 mg/kg) and intravenous (1 mg/kg) IQ-1 administration in rats. IQ-1 and its major metabolite ketone 11H-indeno[1,2-b]quinoxalin-11-one (IQ-18) were isolated from plasma samples by liquid–liquid extraction. IQ-1 (E-isomer) and IQ-18 were simultaneously quantified in plasma by the validated method of liquid chromatography with triple quadrupole mass spectrometry (HPLC–MS/MS). The absolute bioavailability of IQ-1 was < 1.5%. Cmax values were 24.72 ± 4.30, 25.66 ± 7.11 and 37.61 ± 3.53 ng/mL after single oral administration of IQ-1 at doses of 25, 50 and 100 mg/kg, respectively. IQ-1 exhibited dose proportionality at 50–100 mg/kg dose levels, whereas its pharmacokinetics was not dose proportional over the range of 25–50 mg/kg. IQ-18 demonstrated the invariance of the dose-normalized Cmax. In this study we systematically elucidated the absorption characteristics of IQ-1 in rat gastrointestinal tract and provided better understanding of IQ-1 pharmacology for the future development of a new formulations and therapeutic optimisation. | ||
| 336 | |a Текстовый файл | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |t Xenobiotica |c London |n Taylor & Francis Group | |
| 463 | 1 | |t Vol. 54, iss. 1 |v P. 18-25 |d 2024 | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a bioavailability | |
| 610 | 1 | |a dose proportionality | |
| 610 | 1 | |a preclinical pharmacokinetics | |
| 610 | 1 | |a liquid chromatography-mass spectrometry | |
| 610 | 1 | |a absorption | |
| 701 | 1 | |a Frelikh |b G. A. |g Galina Andreevna | |
| 701 | 1 | |a Yanovskaya |b E. A. |g Elena Anatoljevna | |
| 701 | 1 | |a Lakeev |b A. P. |g Aleksandr Pavlovich | |
| 701 | 1 | |a Chernysheva |b G. A. |3 Galina Anatoljevna | |
| 701 | 1 | |a Smolyakova |b V. I. |g Vera Ivanovna | |
| 701 | 1 | |a Kovrizhina |b A. R. |c biotechnology specialist |c Research Engineer of Tomsk Polytechnic University |f 1995- |g Anastasia Ruslanovna |9 22266 | |
| 712 | 0 | 2 | |a National Research Tomsk Polytechnic University |9 27197 |
| 801 | 0 | |a RU |b 63413507 |c 20240605 |g RCR | |
| 856 | 4 | |u https://doi.org/10.1080/00498254.2023.2299686 |z https://doi.org/10.1080/00498254.2023.2299686 | |
| 942 | |c CR | ||